Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Index by author

April 1, 2023; Volume 64,Issue 4

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 10A;

Editor’s Page

  • You have access
    Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?
    Henryk Barthel
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 503-504; DOI: https://doi.org/10.2967/jnumed.123.265667

Discussions With Leaders

  • You have access
    Nuclear Medicine from a Novel Perspective: Buvat and Weber Talk with OpenAI’s ChatGPT
    Irène Buvat and Wolfgang Weber
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 505-507; DOI: https://doi.org/10.2967/jnumed.123.265636

State of the Art

  • You have access
    Functional Imaging of Chemobrain: Usefulness of Nuclear Medicine in the Fog Coming After Cancer
    Agostino Chiaravalloti, Luca Filippi, Marco Pagani and Orazio Schillaci
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 508-514; DOI: https://doi.org/10.2967/jnumed.121.263294

Continuing Education

  • You have access
    Role of 18F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica
    Riemer H.J.A. Slart, Pieter H. Nienhuis, Andor W.J.M. Glaudemans, Elisabeth Brouwer, Olivier Gheysens and Kornelis S.M. van der Geest
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 515-521; DOI: https://doi.org/10.2967/jnumed.122.265016

Hot Topics

  • You have access
    The Latest Advances in Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors
    Elif Hindié, Eric Baudin, Rodney J. Hicks and David Taïeb
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 522-524; DOI: https://doi.org/10.2967/jnumed.122.264422

Appropriate Use Criteria

  • You have access
    Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema
    Kevin J. Donohoe, Brett J. Carroll, David K. V. Chung, Elizabeth H. Dibble, Emilia Diego, Francesco Giammarile, Frederick D. Grant, Stephen Y. Lai, Hannah Linden, Megan E. Miller, Neeta Pandit-Taskar, Nicholas E. Tawa and Sergi Vidal-Sicart
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 525-528; DOI: https://doi.org/10.2967/jnumed.123.265560

Oncology

  • Clinical

    • Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by <sup>90</sup>Y Radioembolization: A Multicenter Retrospective Study
      You have access
      Real-Life Experience in the Treatment of Intrahepatic Cholangiocarcinoma by 90Y Radioembolization: A Multicenter Retrospective Study
      Benedikt M. Schaarschmidt, Roman Kloeckner, Thomas Dertnig, Aydin Demircioglu, Lukas Müller, Timo Alexander Auer, Daniel Pinto dos Santos, Verena Steinle, Matthias Miederer, Bernhard Gebauer, Sonia Radunz, Stefan Kasper, Manuel Weber and Jens Theysohn
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 529-535; DOI: https://doi.org/10.2967/jnumed.122.264598
    • Prognostic Value of <sup>18</sup>F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen
      You have access
      Prognostic Value of 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma Treated with a Risk-Adapted Immunochemotherapy Regimen
      Laure Michaud, Kurt Bantilan, Audrey Mauguen, Craig H. Moskowitz, Andrew D. Zelenetz and Heiko Schöder
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 536-541; DOI: https://doi.org/10.2967/jnumed.122.264740
  • Basic

    • FEATURED BASIC SCIENCE ARTICLE

      • Cure of Disseminated Human Lymphoma with [<sup>177</sup>Lu]Lu-Ofatumumab in a Preclinical Model
        Open Access
        Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model
        Kyuhwan Shim, Mark S. Longtine, Diane S. Abou, Mark J. Hoegger, Richard S. Laforest, Daniel L.J. Thorek and Richard L. Wahl
        Journal of Nuclear Medicine April 1, 2023, 64 (4) 542-548; DOI: https://doi.org/10.2967/jnumed.122.264816
    • <sup>225</sup>Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
      Open Access
      225Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
      A. Paden King, Nicholas T. Gutsche, Natarajan Raju, Stanley Fayn, Kwamena E. Baidoo, Meghan M. Bell, Colleen S. Olkowski, Rolf E. Swenson, Frank I. Lin, Samira M. Sadowski, Stephen S. Adler, Nikki A. Thiele, Justin J. Wilson, Peter L. Choyke and Freddy E. Escorcia
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 549-554; DOI: https://doi.org/10.2967/jnumed.122.264707
    • Preclinical Evaluation of <sup>89</sup>Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis
      Open Access
      Preclinical Evaluation of 89Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis
      Olli Moisio, Jenni Virta, Emrah Yatkin, Heidi Liljenbäck, Senthil Palani, Riikka Viitanen, Maxwell W.G. Miner, Vesa Oikonen, Tuula Tolvanen, Danielle J. Vugts, Pekka Taimen, Xiang-Guo Li, Maija Hollmén, Sirpa Jalkanen and Anne Roivainen
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 555-560; DOI: https://doi.org/10.2967/jnumed.122.264725

Theranostics

  • Clinical

    • Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy
      You have access
      Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy
      Michael Oeverhaus, Jana Koenen, Nikolaos Bechrakis, Mareile Stöhr, Ken Herrmann, Wolfgang P. Fendler, Anja Eckstein and Manuel Weber
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 561-566; DOI: https://doi.org/10.2967/jnumed.122.264660
    • FEATURED ARTICLE OF THE MONTH

      • Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumors
        You have access
        Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors
        Lisa Bodei, Nitya Raj, Richard K. Do, Audrey Mauguen, Simone Krebs, Diane Reidy-Lagunes and Heiko Schöder
        Journal of Nuclear Medicine April 1, 2023, 64 (4) 567-573; DOI: https://doi.org/10.2967/jnumed.122.264363
    • BRIEF COMMUNICATION

      • Safety and Survival Outcomes of <sup>177</sup>Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior <sup>223</sup>Ra treatment: The RALU Study
        Open Access
        Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study
        Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen and Oliver Sartor
        Journal of Nuclear Medicine April 1, 2023, 64 (4) 574-578; DOI: https://doi.org/10.2967/jnumed.122.264456
    • Phase III Study of <sup>18</sup>F-PSMA-1007 Versus <sup>18</sup>F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study
      Open Access
      Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study
      Pierre Olivier, Anne-Laure Giraudet, Andrea Skanjeti, Charles Merlin, Pierre Weinmann, Ines Rudolph, Alexander Hoepping and Mathieu Gauthé
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 579-585; DOI: https://doi.org/10.2967/jnumed.122.264743
    • Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus <sup>18</sup>F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial
      You have access
      Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial
      Ismaheel O. Lawal, Ashesh B. Jani, Omotayo A. Adediran, Subir Goyal, Olayinka A. Abiodun-Ojo, Vishal R. Dhere, Charles V. Marcus, Shreyas S. Joshi, Viraj A. Master, Pretesh R. Patel, Mark Goodman, Joseph W. Shelton, Omer Kucuk, Bruce Hershatter, Bridget Fielder, Raghuveer K. Halkar and David M. Schuster
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 586-591; DOI: https://doi.org/10.2967/jnumed.122.264832
    • A Pilot Study of <sup>68</sup>Ga-PSMA11 and <sup>68</sup>Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy
      You have access
      A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy
      Heying Duan, Pejman Ghanouni, Bruce Daniel, Jarrett Rosenberg, Guido A. Davidzon, Carina Mari Aparici, Christian Kunder, Geoffrey A. Sonn and Andrei Iagaru
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 592-597; DOI: https://doi.org/10.2967/jnumed.122.264783
    • <sup>18</sup>F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in Men
      You have access
      18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in Men
      Pedro Fragoso Costa, Lukas Püllen, Claudia Kesch, Ulrich Krafft, Stephan Tschirdewahn, Alexandros Moraitis, Jan Philipp Radtke, Saskia Ting, Michael Nader, Jasmin Wosniack, David Kersting, Katharina Lückerath, Ken Herrmann, Wolfgang Peter Fendler, Boris Alexander Hadaschik and Christopher Darr
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 598-604; DOI: https://doi.org/10.2967/jnumed.122.264670
    • Prognostic Value of Tumor Volume Assessment on PSMA PET After <sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
      You have access
      Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
      Felix Kind, Ann-Christin Eder, Cordula A. Jilg, Philipp E. Hartrampf, Philipp T. Meyer, Juri Ruf and Kerstin Michalski
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 605-610; DOI: https://doi.org/10.2967/jnumed.122.264489
    • A Single-Arm, Low-Dose, Prospective Study of <sup>177</sup>Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
      You have access
      A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
      Guochang Wang, Jie Zang, Yuanyuan Jiang, Qingxing Liu, Huimin Sui, Rongxi Wang, Xinrong Fan, Jingjing Zhang, Zhaohui Zhu and Xiaoyuan Chen
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 611-617; DOI: https://doi.org/10.2967/jnumed.122.264857
    • You have access
      Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
      Mahnoosh Naeimi, Peter L. Choyke, Katharina Dendl, Yuriko Mori, Fabian Staudinger, Tadashi Watabe, Stefan A. Koerber, Manuel Röhrich, Jürgen Debus, Clemens Kratochwil, Uwe Haberkorn and Frederik L. Giesel
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 618-622; DOI: https://doi.org/10.2967/jnumed.122.264941
    • INVITED PERSPECTIVE

      • You have access
        Could FAP-Targeted Molecular Imaging Replace 18F-FDG for Standard-of-Care Oncologic PET?
        Raghava Kashyap and Aravind S. Ravi Kumar
        Journal of Nuclear Medicine April 1, 2023, 64 (4) 623-624; DOI: https://doi.org/10.2967/jnumed.122.265003
    • Response Prediction Using <sup>18</sup>F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy
      You have access
      Response Prediction Using 18F-FAPI-04 PET/CT in Patients with Esophageal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy
      Xinying Hu, Tao Zhou, Jiazhong Ren, Jinghao Duan, Hongbo Wu, Xiaoli Liu, Zhengshuai Mu, Ning Liu, Yuchun Wei and Shuanghu Yuan
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 625-631; DOI: https://doi.org/10.2967/jnumed.122.264638
    • <sup>18</sup>F-AlF-NOTA-Octreotide Outperforms <sup>68</sup>Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
      You have access
      18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study
      Elin Pauwels, Frederik Cleeren, Térence Tshibangu, Michel Koole, Kim Serdons, Lennert Boeckxstaens, Jeroen Dekervel, Timon Vandamme, Willem Lybaert, Bliede Van den Broeck, Annouschka Laenen, Paul M. Clement, Karen Geboes, Eric Van Cutsem, Sigrid Stroobants, Chris Verslype, Guy Bormans and Christophe M. Deroose
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 632-638; DOI: https://doi.org/10.2967/jnumed.122.264563
  • Basic

    • Preclinical Evaluation of <sup>68</sup>Ga- and <sup>177</sup>Lu-Labeled Integrin α<sub>v</sub>β<sub>6</sub>-Targeting Radiotheranostic Peptides
      You have access
      Preclinical Evaluation of 68Ga- and 177Lu-Labeled Integrin αvβ6-Targeting Radiotheranostic Peptides
      Tanushree Ganguly, Nadine Bauer, Ryan A. Davis, Cameron C. Foster, Rebecca E. Harris, Sven H. Hausner, Emilie Roncali, Sarah Y. Tang and Julie L. Sutcliffe
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 639-644; DOI: https://doi.org/10.2967/jnumed.122.264749

Cardiovascular

  • Clinical

    • Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using <sup>11</sup>C-Acetate PET
      You have access
      Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using 11C-Acetate PET
      Jens Sorensen, Johannes Bergsten, Tomasz Baron, Lovisa Holm Orndahl, Tanja Kero, Tomas Bjerner, Eva-Maria Hedin, Hendrik J. Harms, Rafael Astudillo and Frank A. Flachskampf
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 645-651; DOI: https://doi.org/10.2967/jnumed.122.264945

AI/Advanced Image Analysis

  • Basic

    • Deep Learning Coronary Artery Calcium Scores from SPECT/CT Attenuation Maps Improve Prediction of Major Adverse Cardiac Events
      You have access
      Deep Learning Coronary Artery Calcium Scores from SPECT/CT Attenuation Maps Improve Prediction of Major Adverse Cardiac Events
      Robert J.H. Miller, Konrad Pieszko, Aakash Shanbhag, Attila Feher, Mark Lemley, Aditya Killekar, Paul B. Kavanagh, Serge D. Van Kriekinge, Joanna X. Liang, Cathleen Huang, Edward J. Miller, Timothy Bateman, Daniel S. Berman, Damini Dey and Piotr J. Slomka
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 652-658; DOI: https://doi.org/10.2967/jnumed.122.264423

Physics and Instrumentation

  • Basic

    • Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
      Open Access
      Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
      Seung Kwan Kang, Daewoon Kim, Seong A Shin, Yu Kyeong Kim, Hongyoon Choi and Jae Sung Lee
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 659-666; DOI: https://doi.org/10.2967/jnumed.122.264414

Illustrated Post

  • You have access
    Detecting CXCR4 Expression in Meningioma on 68Ga-Pentixafor PET/MRI
    Simone Krebs, Jazmin Schwartz, Christian Grommes, Robert J. Young, Heiko Schöder and Marius E. Mayerhoefer
    Journal of Nuclear Medicine April 1, 2023, 64 (4) 667-668; DOI: https://doi.org/10.2967/jnumed.122.265127

Departments

  • Recruitment

    • You have access
      Recruitment
      Journal of Nuclear Medicine April 1, 2023, 64 (4) 9A;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 64 (4)
Journal of Nuclear Medicine
Vol. 64, Issue 4
April 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors
  • Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model
Sign up for alerts

Jump to

  • This Month in JNM
  • Editor’s Page
  • Discussions With Leaders
  • State of the Art
  • Continuing Education
  • Hot Topics
  • Appropriate Use Criteria
  • Oncology
    • Clinical
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Theranostics
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
      • BRIEF COMMUNICATION
      • INVITED PERSPECTIVE
    • Basic
  • Cardiovascular
    • Clinical
  • AI/Advanced Image Analysis
    • Basic
  • Physics and Instrumentation
    • Basic
  • Illustrated Post
  • Departments
    • Recruitment
  • Most Cited
  • Most Read
Loading
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
  • Total-Body Perfusion Imaging with [11C]-Butanol
More...
SNMMI

© 2025 SNMMI

Powered by HighWire